Additional file 1: of Group B streptococcus (GBS) is an important pathogen in human disease- but what about in cystic fibrosis?

Clinical and microbiologic characteristics of individuals with CF at the time of first GBS positive sputum culture. (XLSX 39 kb

Additional file 1: Figure S1. of The effects of inhaled aztreonam on the cystic fibrosis lung microbiome

Schematic representation of a theoretical patient’s biobanked samples of frozen whole sputum relative to initiation of AZLI. Days from initiation of AZLI are listed on the x-axis. Samples could have been collected at any time point during the 1 year prior to and subsequent to AZLI initiation and samples may have been collected on/off therapy as treatments are administered in 28 day cycles or during cycling of other inhaled antibiotics. Samples may have also been collected during the use of systemic antibiotics. Prior Inh-Abx refers to prior chronic suppressive antibacterial treatment. (TIF 856 kb

Trial Profile.

<p>Trial Profile.</p

Pulmonary Exacerbations and Hospitalizations by Treatment Group - 24 Week Treatment Period.

<p>Pulmonary Exacerbations and Hospitalizations by Treatment Group - 24 Week Treatment Period.</p

Time to First Pulmonary Exacerbation Requiring Oral or Intravenous Antibiotics.

<p>Blue dashed line = placebo-treated patients. Black solid line = itraconazole-treated patients. The median time to first exacerbation was 77 days for the itraconazole group and 134 days for the placebo group, log-rank P = 0.35. Hash marks = censored observations.</p

Changes from Baseline in FEV1 Over the 48-Week Study.

<p>Blue dashed line = placebo-treated patients. Black solid line = itraconazole-treated patients. 95% confidence intervals are indicated by the error bars around the mean values.</p

Adverse Events.

<p>Adverse Events.</p

Baseline Characteristics of the Randomized Patients.

<p>Baseline Characteristics of the Randomized Patients.</p